Cargando…

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial

Aims: The efficacy of antiplatelet therapy may vary among different disease subtypes. Prasugrel is generally a more potent, consistent, and fast-acting platelet inhibitor than clopidogrel. This sub-analysis of the phase III comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitazono, Takanari, Toyoda, Kazunori, Kitagawa, Kazuo, Nagao, Takehiko, Yamagami, Hiroshi, Uchiyama, Shinichiro, Tanahashi, Norio, Matsumoto, Masayasu, Minematsu, Kazuo, Nagata, Izumi, Nishikawa, Masakatsu, Nanto, Shinsuke, Ikeda, Yasuo, Shirai, Toshiaki, Abe, Kenji, Ogawa, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957026/ https://www.ncbi.nlm.nih.gov/pubmed/32493881 http://dx.doi.org/10.5551/jat.56093

Ejemplares similares

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)
por: Kitazono, Takanari, et al.
Publicado: (2023)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

Rivaroxaban administration after acute ischemic stroke: The RELAXED study
por: Yasaka, Masahiro, et al.
Publicado: (2019)

Final Results of Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS)
por: Uchiyama, Shinichiro, et al.
Publicado: (2015)

Clinical Characteristics of Transient Ischemic Attack Patients with Atrial Fibrillation: Analyses of a Multicenter Retrospective Study
por: Hama, Yuka, et al.
Publicado: (2015)

Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation
por: Koge, Junpei, et al.
Publicado: (2022)

Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS
por: Kitagawa, Kazuo, et al.
Publicado: (2017)

Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA
por: Kitagawa, Kazuo, et al.
Publicado: (2019)

Japanese and Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke: A Five-Year Risk Analysis of Stroke and Vascular Events
por: Uchiyama, Shinichiro, et al.
Publicado: (2021)

Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event
por: Hosomi, Naohisa, et al.
Publicado: (2018)

Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study
por: Nezu, Tomohisa, et al.
Publicado: (2020)

Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS
por: Hosomi, Naohisa, et al.
Publicado: (2020)

Practical “1-2-3-4-Day” Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study
por: Kimura, Shunsuke, et al.
Publicado: (2022)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Long-Term Effect of Pravastatin on Carotid Intima–Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke)
por: Koga, Masatoshi, et al.
Publicado: (2018)

Factors Associated with Intima-Media Complex Thickness of the Common Carotid Artery in Japanese Noncardioembolic Stroke Patients with Hyperlipidemia: The J-STARS Echo Study
por: Wada, Shinichi, et al.
Publicado: (2018)

Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial
por: Toyoda, Kazunori, et al.
Publicado: (2015)

Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis
por: Toyoda, Kazunori, et al.
Publicado: (2022)

Futile complete recanalization: patients characteristics and its time course
por: Kitano, Takaya, et al.
Publicado: (2020)

THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
por: Koga, Masatoshi, et al.
Publicado: (2014)

Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
por: Hoshino, Haruhiko, et al.
Publicado: (2023)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
por: Iijima, Mutsumi, et al.
Publicado: (2017)

Pramipexole-induced antecollis in patients with Parkinson's disease: Two cases and literature review
por: Iijima, Mutsumi, et al.
Publicado: (2015)

The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study
por: Hosomi, Naohisa, et al.
Publicado: (2015)

Author Correction: Time–outcome relationship in acute large-vessel occlusion exists across all ages: subanalysis of RESCUE-Japan Registry 2
por: Todo, Kenichi, et al.
Publicado: (2021)

Time–outcome relationship in acute large-vessel occlusion exists across all ages: subanalysis of RESCUE-Japan Registry 2
por: Todo, Kenichi, et al.
Publicado: (2021)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)
por: Ogawa, Satoshi, et al.
Publicado: (2018)

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS
por: Ikeda, Takanori, et al.
Publicado: (2021)

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study
por: Ikeda, Takanori, et al.
Publicado: (2022)

Clinical, Laboratory, and Imaging Characteristics of Transient Ischemic Attack Caused by Large Artery Lesions: A Comparison between Carotid and Intracranial Arteries
por: Uehara, Toshiyuki, et al.
Publicado: (2015)

Predictors of Stroke Events in Patients with Transient Ischemic Attack Attributable to Intracranial Stenotic Lesions
por: Uehara, Toshiyuki, et al.
Publicado: (2017)

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
por: Murakawa, Yuji, et al.
Publicado: (2020)

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
por: Ikeda, Takanori, et al.
Publicado: (2019)

Prasugrel-Induced Hypersensitivity Skin Reaction
por: Kim, Soo-Han, et al.
Publicado: (2014)

Prasugrel for Secondary Prevention of Thrombotic Stroke
por: Yagita, Yoshiki
Publicado: (2023)

Review of Prasugrel for the Secondary Prevention of Atherothrombosis
por: Spinler, Sarah A., et al.
Publicado: (2009)

Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS)
por: Nagai, Yoji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5q18tnu20suugutfprs1697hkn